Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: Economic evaluation within a randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 424-427

  Fautrel, B ^a,b   Benhamou, M ^a,b   Breban, M ^c,d   Roy, C ^e,f   Lenoir, C ^g   Trape, G ^g   Baleydier, A ^h   Ravaud, P ^e,f,i   Dougados, M ^i,j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d INSTITUT COCHIN   (France)

^e INSERM   (France)

^f BICHAT HOSPITAL   (France)

^g Schering Plough Pharmaceuticals   (France)

^h RCTS   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j Institut Cochin   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749114133     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.103887     Document Type: Article

References (24)

1. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
2. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316- 20.
3. Pham T, Landewe R, van der Linden S, et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 2006;65:1620-5.
4. Zochling J, van der Heijde D, DougadosM, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
5. Gossec L, Le Henanff A, Breban M, et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford) 2006;45:859-62.
6. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of treatment with infliximab in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versis on-demand regimen. Arthritis Rheum 2007;58:88-97.
7. Garrett S, Jenkinson T, Kennedy LG. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
8. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
9. Clarke AE, Esdaile JM, Bloch DA, et al. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59.
10. Bakker CH, Rutten-van Molken M, van Doorslaer E, et al. Health related utility measurement in rheumatology: an introduction. Patient Educ Couns 1993;20:145-52.
11. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
12. Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res 1998;7:155-66.
13. Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004;42:1125-31.
14. Nord E. Health state values from multiattribute utility instruments need correction. Ann Med 2001;33:371-4.
15. Boonen A, van der Heijde D, Landewe R, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40.
16. Boonen A, van der Heijde D, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003;62:741-7.
17. Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
18. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
19. Listing J, Brandt J, Rudwaleit M, et al. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670-2.
20. van der Heijde D, Han C, DeVlam K, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569-74.
21. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004;43:1158-66.
22. Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006;33:732-40.
23. Boonen A, van der Heijde D, Severens JL, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006;65:201-8.
24. McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.